Fair points. But Immutep has moved to a new phase so the market...

Fair points. But Immutep has moved to a new phase so the market behavior will be different, imo. We no longer have to fear failed trial results.

Immutep’s prime asset has been de-risked by the “fast track” designation of the FDA. Particularly as they fast tracked it into 1st line head and neck treatment from its trial in second line. According to the seeking Alpha article this is very unusual.

Now I can read trial results from an educated layman’s point of view with interest in the topic and Tacti-002 looks great. But the FDA have the smartest people in the business running the rule over these trials. Efti is the goods.

With so many trials in the pipeline, positive Efti news is never far away. The only thing that can derail us is market volatility. So if you aren’t spooked by sudden falls precipitated by index volatility then it will be a great ride